TrialCardiovascular diabetology2022

Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.

Andrei C Sposito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.